VERAXA Biotech is a technology-based company, located in Heidelberg/Germany. We revolutionize antibody discovery and conjugation for targeted therapy.

Our proprietary high throughput droplet-based microfluidic platform can screen entire immune repertoires with millions of antibody-secreting cells for binding, functionality, and internalization on a single-cell level. Several cellular determinants can be monitored simultaneously, and our flexible software framework allows us to easily customize assays to specific biological needs. The focus on biological relevant signals together with our robust and versatile screening platform enables us to find highly specific and functional antibodies and reduces the risk of drug developmental stages. 

Our proprietary ADC technology utilizes genetic code expansion and fastest bioorthogonal click chemistry to selectively conjugate payloads at a freely selectable position of antibodies/proteins/enzymes. Incorporating non-canonical amino acid in vivo enables the generation of homogenous ADCs with precise and highly narrow drug-to-antibody ratios. Conjugation of the payload is efficient and independent of solvent or pH. Our site-specific ADC technology allows tailoring of key biological determinants to improve pharmacokinetics and pharmacodynamic properties yielding superior drugs.